These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10956312)

  • 21. Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses.
    Dzau VJ; Creager MA
    Cardiol Clin; 1989 Feb; 7(1):119-30. PubMed ID: 2650868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cardiovascular pharmacology (IX). Angiotensin-converting enzyme inhibitors in hypertension and heart failure].
    de Teresa E; Espinosa JS; Gómez Doblas JJ
    Rev Esp Cardiol; 1995 Feb; 48(2):128-41. PubMed ID: 7886264
    [No Abstract]   [Full Text] [Related]  

  • 23. The renin-angiotensin system as a target for therapeutic intervention.
    Swales JD
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S1-5. PubMed ID: 7898088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using ACE inhibitors appropriately.
    Bicket DP
    Am Fam Physician; 2002 Aug; 66(3):461-8. PubMed ID: 12182524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is neurohormonal activation a major determinant of the response to ACE inhibition in left ventricular dysfunction and heart failure?
    Sigurdsson A; Swedberg K
    Br Heart J; 1994 Sep; 72(3 Suppl):S75-80. PubMed ID: 7946809
    [No Abstract]   [Full Text] [Related]  

  • 26. Preventing and reversing target organ damage by treatment of the renin-angiotensin system.
    Krakoff LR; Rajasekharaiah V
    Mt Sinai J Med; 1998 Mar; 65(2):125-32. PubMed ID: 9520516
    [No Abstract]   [Full Text] [Related]  

  • 27. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects.
    Falkenhahn M; Gohlke P; Paul M; Stoll M; Unger T
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S6-13. PubMed ID: 7898096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Angiotensin-converting enzyme inhibitors in the treatment of heart failure: toward a change in the natural history of the disease].
    Martín Luengo C; Arribas Jiménez A; Nieto Ballestero F; Diego Domínguez M; Cascón Bueno M; Pabón Osuna P; Sala Sánchez-Castillo A
    Rev Esp Cardiol; 1993 Mar; 46(3):131-45. PubMed ID: 8488316
    [No Abstract]   [Full Text] [Related]  

  • 29. Overview of angiotensin II-receptor antagonists.
    Pitt B; Konstam MA
    Am J Cardiol; 1998 Nov; 82(10A):47S-49S. PubMed ID: 9860359
    [No Abstract]   [Full Text] [Related]  

  • 30. [Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency].
    Kolloch R; Offers E
    Dtsch Med Wochenschr; 2001 Nov; 126(47):1342-7. PubMed ID: 11719860
    [No Abstract]   [Full Text] [Related]  

  • 31. [The role of angiotensin converting enzyme inhibition for therapy of patients with hypertension and heart failure].
    Hoyen HA; Alpert JS
    Cardiology; 1993; 82 Suppl 1():3-19. PubMed ID: 8519018
    [No Abstract]   [Full Text] [Related]  

  • 32. Do inhibitors of the rennin-angiotensin system prevent chronic kidney disease?
    Rayner B
    Cardiovasc J Afr; 2010; 21(1):3-6. PubMed ID: 20224837
    [No Abstract]   [Full Text] [Related]  

  • 33. [Angiotensin-converting enzyme (ACE) inhibitors in cardiac decompensation; from randomized study to individual patient].
    van Vlies B
    Ned Tijdschr Geneeskd; 1992 Sep; 136(37):1796-8. PubMed ID: 1407135
    [No Abstract]   [Full Text] [Related]  

  • 34. [Summary of seminar on renin-angiotensin system and angiotensin converting enzyme inhibitor].
    Zhonghua Yi Xue Za Zhi; 1995 Feb; 75(2):70-3. PubMed ID: 7767770
    [No Abstract]   [Full Text] [Related]  

  • 35. Renal effects of angiotensin-I converting enzyme inhibitors.
    Gans RO; Hoorntje SJ; Donker AJ
    Neth J Med; 1988 Jun; 32(5-6):247-64. PubMed ID: 3292962
    [No Abstract]   [Full Text] [Related]  

  • 36. Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials.
    Moukarbel GV; Solomon SD
    Curr Heart Fail Rep; 2008 Dec; 5(4):197-203. PubMed ID: 19032914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors.
    Greenwald L; Becker RC
    Am Heart J; 1994 Nov; 128(5):997-1009. PubMed ID: 7942494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetes complications and the renin-angiotensin system.
    Perkins BA; Aiello LP; Krolewski AS
    N Engl J Med; 2009 Jul; 361(1):83-5. PubMed ID: 19571288
    [No Abstract]   [Full Text] [Related]  

  • 39. [Direct renin inhibition: a new and promising treatment principle in heart failure?].
    Mahfoud F; Ukena C; Böhm M
    Dtsch Med Wochenschr; 2009 Apr; 134(15):759-62. PubMed ID: 19340755
    [No Abstract]   [Full Text] [Related]  

  • 40. Angiotensin converting enzyme inhibitors: are they preferred first-line therapy?
    Glasser SP
    Curr Hypertens Rep; 2000 Aug; 2(4):392-7. PubMed ID: 10981175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.